Compare GE Aerospace (GE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs State Street SPDR S&P Biotech ETF — how do they compare? GE Aerospace trades at $338 (market cap $375.97B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: GE Aerospace pays a 0.52% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, GE Aerospace nearer its low. Which is the better fit depends on your goals.
| GE | XBI | |
|---|---|---|
Market Cap | $375.97B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $378.68 | $164.28 |
52-Week Low | $259.00 | $85.16 |
Enterprise Value | $385.26B | — |
Dividend Yield | 0.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.
Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
